gene_symbol
UNKNOWN
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Dinutuximab binds GD2 on tumor cells, then engages Fcγ receptor–bearing effectors for ADCC and recruits C1q to activate complement for CDC. C1q-expressing cells are not targeted or killed; complement is an effector in killing GD2-positive cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Initiates classical complement pathway for CDC upon IgG1 Fc binding
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06450041
disease_id_num_tar_ref
1626
drug_id_num_tar_ref
4400